NKTR
Nektar Therapeutics
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Nektar Therapeutics
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Nektar Therapeutics has 3 disclosed suppliers and 11 disclosed customers in SEC filings.
SentenceRevenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39 %, 18 %, 17 %, 12 % and 10 % of our revenue, respectively, for the year ended December 31, 2024.
basisNKTR FY2025 revenue $55M
NKTR 10-Kaccession 0001193125-26-104547
SentenceRevenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39 %, 18 %, 17 %, 12 % and 10 % of our revenue, respectively, for the year ended December 31, 2024.
basisNKTR FY2025 revenue $55M
NKTR 10-Kaccession 0001193125-26-104547
SentenceRevenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39 %, 18 %, 17 %, 12 % and 10 % of our revenue, respectively, for the year ended December 31, 2024.
basisNKTR FY2025 revenue $55MAZN FY2025 revenue $77.0B
SentenceRevenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39 %, 18 %, 17 %, 12 % and 10 % of our revenue, respectively, for the year ended December 31, 2024.
basisNKTR FY2025 revenue $55MPFE FY2025 revenue $62.6B
SentenceRevenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39 %, 18 %, 17 %, 12 % and 10 % of our revenue, respectively, for the year ended December 31, 2024.
basisNKTR FY2025 revenue $55M
NKTR 10-Kaccession 0001193125-26-104547
Table…base rental revenues, as defined below, as of December 31, 2025
| Tenant Name (1) | Region | Annualized Base Rental Revenue (in thousands) (2) | Rentable Square Feet | Percentage of Total Annualized Base Rental Revenue (2) | Percentage of Total Rentable Square Feet | Year(s) of Significant Lease Expiration(s) (3) | Weighted Average Remaining Lease Term (Years) | |
|---|---|---|---|---|---|---|---|---|
| 19 | Nektar Therapeutics, Inc. | San Francisco Bay Area | 12,297 | 135,974 | 1.6% | 0.8% | 2030 | 4.1 |
SentenceUnder the terms of the supply agreements, Gannet BioChem has agreed to manufacture and supply the PEG reagents for use in clinical trials of these drug candidates at prices defined within the agreements.
NKTR 10-Kaccession 0001193125-26-104547
SentenceIn the past, we have received a number of significant payments from collaboration agreements and other significant transactions, including $1.9 billion in total consideration received under our arrangement with BMS, development cost reimbursements from BMS, and a $150.0 million upfront payment from Eli Lilly and Company for our collaboration agreement for rezpegaldesleukin.
SentenceIn the past, we have received a number of significant payments from collaboration agreements and other significant transactions, including $1.9 billion in total consideration received under our arrangement with BMS, development cost reimbursements from BMS, and a $150.0 million upfront payment from Eli Lilly and Company for our collaboration agreement for rezpegaldesleukin.
SentenceOn December 2, 2024, we completed the sale of the Facility and assigned our manufacturing and supply agreements to Gannet BioChem, an affiliate of Ampersand Management LLC d/b/a Ampersand Capital Partners (Ampersand) for consideration of $64.7 million in cash, net of transaction costs, and an approximate 20% equity interest at the time of close in Gannet BioChem.
NKTR 10-Kaccession 0001193125-26-104547
SentenceOn March 4, 2024, Nektar and HCR amended the 2020 Purchase and Sale Agreement to remove the cap on the royalties in exchange for $15.0 million.
NKTR 10-Kaccession 0001193125-26-104547
SentenceIn 2012, we sold all of our rights to receive royalties from CIMZIA ® (for the treatment of Crohn's disease and other autoimmune indications) and MIRCERA ® (for the treatment of anemia associated with chronic kidney disease) under our collaborations with UCB Pharma (UCB) and F. Hoffmann-La Roche Ltd, respectively, to RPI Finance Trust (RPI), an affiliate of Royalty Pharma for $124.0 million.
NKTR 10-Kaccession 0001193125-26-104547
SentenceOn February 24, 2025, we announced that we had entered into a collaboration agreement with TrialNet to evaluate rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus in a Phase 2 study. TrialNet will conduct the study with funding from the National Institutes of Health, primarily through the Special Statutory Funding Program for Type 1 Diabetes through the National Institute of Diabetes and Digestive and Kidney Diseases. Nektar will supply rezpegaldesleukin for the study and will retain all rights to the rezpegaldesleukin program under the collaboration.
NKTR 10-Kaccession 0001193125-26-104547
Nektar Therapeutics
38.71
Expected move
Inputsstraddle ±12.8%
spot 38.87exp Nov 20ATM strike 39ATM straddle 5.88IV 79%